CardioBrief: FOURIER Shows PCSK9 Drugs Work, But Are They Worth It? – MedPage Today
NPR |
CardioBrief: FOURIER Shows PCSK9 Drugs Work, But Are They Worth It?
MedPage Today As it turns out, the PCSK9 inhibitor saga ends not with a bang but a whimper. The results of the highly anticipated FOURIER trial show that the drugs work, though not as powerfully as many had hoped and expected. The question now will be whether the … Did Amgen’s Repatha cut CV risks enough to make it cost-effective? Analysts say no UPDATE 1-Amgen discounts cholesterol drug, but payers want more Cholesterol drug cuts heart risks, spurs new debate on cost |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.